/
Continuous Renal Replacement Therapy (CRRT) Continuous Renal Replacement Therapy (CRRT)

Continuous Renal Replacement Therapy (CRRT) - PowerPoint Presentation

liane-varnes
liane-varnes . @liane-varnes
Follow
513 views
Uploaded On 2016-07-13

Continuous Renal Replacement Therapy (CRRT) - PPT Presentation

Any extracorporeal blood purification therapy intended to substitute for impaired renal function over an extended period of time and applied for or aimed at being applied for 24 hours day ID: 402110

solute blood flow dialysate blood solute dialysate flow clearance membrane fluid filter crrt removal replacement min ultrafiltration diffusion concentration access drug volume

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Continuous Renal Replacement Therapy (CR..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Continuous Renal Replacement Therapy (CRRT)

“ Any extracorporeal blood purification therapy intended to substitute for impaired renal function over an extended period of time and applied for or aimed at being applied for 24 hours /day.” Bellomo R., Ronco C., Mehta R, Nomenclature for Continuous Renal Replacement Therapies, AJKD, Vol 28, No. 5, Suppl 3, November 1996

DefinitionSlide2

Indications

In general:Severe acid-base disordersSevere electrolyte abnormalitiesRefractory volume overloadUremiaIntoxicationsIntensive Care Severe septic shockSlide3

Why CRRT?

Reduces hemodynamic instability preventing secondary ischemiaPrecise Volume control/immediately adaptableUremic toxin removalEffective control of uremia, hypophosphatemia, hyperkalemiaAcid base balance Rapid control of metabolic acidosisElectrolyte management Control of electrolyte imbalancesManagement of sepsis/plasma cytokine filterSlide4

CRRT Circuit

Vascular accessBlood flows MachineryDialyzer Circuit volumeDialysate/ replacement fluid ratesAnticoagulationSlide5

Vascular Access

Double lumen catheter Catheter able to provide sufficient blood flow

11 French and greater

Avoid kinking

Secure connections, make them visible

Right size at the right placeSlide6

Vascular Access

PrinciplesVessel(s) and catheters should be large enough to permit blood flow rates > 300 mls/minProblemsPoor flow (high positive/negative pressures)BleedingClottingInfectionVenous stenosisSlide7

Recirculation

Access recirculation may limit clearancesSubclavian 4.1%Femoral 13.5 cm - 22.8%Femoral 19.5 cm - 12.6%(@Blood flow 300 ml/min)More problematic in IHD than CRRT.Slide8

Mechanisms of Solute Removal

DiffusionUltrafiltrationDiffusion + UltrafiltrationAdsorbtionSlide9
Slide10

Ultrafiltration

Pressure

Membrane

Uf

Uf

The transfer of solute in a stream of solvent, across a semi-permeable membrane, mediated by a hydrostatic force

Membrane

Coffee maker analogy of

Ultrafiltration

Removal of large volumes of solute and fluid via convectionSlide11

Solute clearance

Membrane

Blood

Dialysate/UltrafiltrateSlide12

Convective solute clearance

Membrane

Blood

UltrafiltrateSlide13

Convective solute clearance

Membrane

Blood

UltrafiltrateSlide14

Convection

: The movement of solutes with a water-flow, “solvent drag”, the movement of membrane-permeable solutes with ultra filtered waterBlood InBlood Out

to waste

(from patient)

(to patient)

HIGH PRESS

LOW PRESSSlide15

SCUF

Slow Continuous Ultrafiltration

Access

Return

Effluent

Fluid removal

Minimal solute clearanceSlide16

SCUF

CVVH

Replacement fluid

Removal

of large volumes of solute and fluid via convection

Replacement of excess UF with sterile replacement fluid

Convective solute clearanceSlide17

CVVH

Continuous Veno-Venous Hemofiltration

Access

Return

Effluent

Replacement

Fluid removal

Fluid replacement

Solute clearance

Convection

Minor amount diffusionSlide18

Extracorporeal Clearance

Hemofiltration clearance (ClHF = Qf x S)

Q

f

=

Ultrafiltration

rate

S =

Seiving

coefficient

Hemodialysis

clearance (

Cl

HD

=

Q

d

x

S

d

)

Q

d

=

Dialysate

flow rate

S

d

=

Dialysate

saturation

Hemodialfiltration

clearance

Cl

HDF = (

Qf x S) + (

Qd x S

d)Slide19

Sieving Coefficient (S)

Capacity of a solute to pass through the hemofilter membrane

S =

C

uf

/ C

p

C

uf

=

solute

concentration

in the

ultrafiltrate

C

p

=

solute

concentration

in the plasma

S = 1 Solute freely passes through the filter

S = 0 Solute does not pass through the filter

Slide20

Element

Sieving Coefficient

Element

Sieving Coefficient

Sodium

0.993

Valine

1.069

Potassium

0.975-0.99

Cystine

1.047

Chloride

1.05-1.088

Methionine

1.0

Bicarbonate

1.12-1.137

Isoleucine

1.010

Calcium

0.64-0.677

Leucine

1.014

Phosphate

1.04

Tyrosine

1.089

Albumin

0.0002-0.01

Phenylalanine

1.078

Urea

1.019-1.05

Lysine

1.080

Creatinine

1.02-1.037

Histidine

1.109

Glucose

1.04

Threonine

1.256

Urate

1.02

Total protein

0.02

magnesium

0.9

Total bilirubin

0.03

Sieving coefficient

Ratio of solute concentration in ultrafiltrate to solute concentration in blood Slide21

Determinants of Sieving Coefficient

Protein bindingOnly unbound drug passes through the filterProtein binding changes in critical illnessDrug membrane interactionsAdsorption of proteins and blood products onto filter

Related to filter age

Decreased efficiency of filterSlide22

Relationship Between Free Fraction (

fu) and Sieving Coefficient (S)Slide23

Principles of Hemodialysis

Solute clearance by diffusionSuitable for removal of small molecules, and most middle moleculesSlide24

Dialysis

The use of diffusion (dialysis fluid) to achieve clearanceSlide25

Diffusive solute clearance

Membrane

Blood

DialysateSlide26

Diffusive solute clearance

Membrane

Blood

DialysateSlide27

Counter current flow

Membrane

Blood

DialysateSlide28

Dialysate Out

Dialysate InBlood InBlood Out

to waste

(from patient)

(to patient)

HIGH

CONCENTRATION

LOW

CONCENTRATIONSlide29

CVVHD

Continuous Veno-Venous Hemodialysis

S

Access

Return

Effluent

Fluid removal

Solute removal

(

small molecules)

Counter-current dialysis flow

Diffusion

Back filtration

DialysateSlide30

Dialysate

Saturation (Sd) Sd = Cd

/ C

p

C

d

=

solute

concentration in the

dialysate

C

p

=

solute

concentration

in the plasma

Decreasing

dialysate

saturation

Increasing molecular weight

Decreases speed of diffusion

Increasing

dialysate

flow rate

Decreases time available for diffusion

Slide31

Dialysate Saturation (S

d)Countercurrent dialysate flow (10 - 30 ml/min) is always less than blood flow (100 - 200 ml/min)Allows complete equilibrium between blood serum and dialysate

Dialysate

leaving filter will be 100% saturated with easily diffusible

solutes

Diffusive clearance will equal

dialysate

flowSlide32

Replacement Fluid/Dialysate

Must contain:SodiumCalcium (except with citrate)Base (bicarbonate, lactate or citrate)May contain:PotassiumPhosphateMagnesiumSlide33

CRRT Set up

The Machine….Slide34

CVVHDF

Continuous Veno-Venous Hemodiafiltration

Replacement

S

Access

Return

Effluent

Dialysate

Fluid removal

Solute removal

(

small and larger solutes)

Diffusion plus ConvectionSlide35

Blood Flow/Blood Pump Speed

Range from 10 to 450 ml/minAverage 125-150 ml/minHigher blood flow could decrease filter clottingFactors affecting QB : - Catheter lumen size -

Blood viscosity

Slide36

Effect of filtration on CVVH

Hematocrit30%Hematocrit60%A filtration fraction of more than 25 - 30% greatly increasesblood viscosity within the circuit, risking clot and malfunction.Slide37

Blood flow requirements for CRRT to maintain filtration fraction at 25%

Ultrafiltration rate (mls/hr)Minimum

Qb

/min

1500

100

2000

130

2500

155

3000

200

4000

265

The degree of blood dehydration can be

estimated by determining the filtration fraction

(FF), which is the fraction of plasma water

removed by

ultrafiltration

:

FF(%) = (UFR x 100) / QP

where QP is the filter plasma flow rate in ml/min.Slide38

Anticoagulation options

None (- if marked coagulopathy)Unfractionated heparinLMW HeparinCitrateDirect Thrombin Inhibitorsr-Hirudin Argatroban Prostacycline

Assessment:

Need ongoing anticoagulation

Risk of bleeding with heparin

2% per day

3.5-10% of deaths

25% of new hemorrhagic episodesSlide39

Impact of filter clotting

Decrease in dialysis doseWasted nursing timeIncrease in costSlide40

Renal Replacement Therapy Dose

Dose = amount of solute clearanceModifications required based on:Patient weightInterruptionsRecirculationSlide41

Dosage Adjustments in CRRT

Loading doses Loading dose depends solely on volume of distributionMaintenance dosesStandard reference tablesBase on measured

loses

Will the drug be removed?

Pharmacokinetic parameters

Protein binding < 70 - 80%

Normal values may not apply to critically ill patients

Volume of distribution < 1 L/kg

Renal clearance > 35%

How often do I dose the drug?

Haemofiltration

: ‘GFR’ 10 - 20 ml/min

Haemofiltration

with dialysis: ‘GFR’ 20 - 50 ml/minSlide42

Dosage Adjustments in CRRT

Frequent blood level determinationsAminoglycosides, vancomycin Reference tablesBennett's tables or the PDR recommendations require an approximation of patient's GFRUsing Bennett's or the PDR’s tables, in most CVVH patients, drug dosing can be adjusted for a ‘GFR’ in the range of 10 to 50 ml/minSlide43
Slide44

Drug Removal During CRRT

Limited to case reports or series of patientsDifferent filter brands, sizes, flow rates

Limited information in many

reports

Artificial

models and predictions have no clinical valueSlide45

< MW = > Elimination

> Blood flow = > Elimination

>

Dialysate

flow = > Elimination

Free available drugSlide46

< VD = > Elimination

> Water solubility = > EliminationSlide47
Slide48
Slide49
Slide50

TOXOKINETICS

MORE THAN OUTCOMESSlide51

Ongoing dilemas in CRRT

ModeClinically still part of the debate (sepsis vs. ARF)DoseRonco TrialRenal StudyATN TrialHigh Volume UltrafiltrationIHD vs CRRTNo diference in outcome in a RCTAnticoagulationSlide52

World practiceHVUF

Ongoing dilemas in CRRTSlide53